The hard to borrow tag was on a few days ago. not on now
•The annual American Society of Hematology meeting is due to start today in New Orleans, where new treatments for chronic lymphocytic leukemia from Gilead Sciences (GILD), Pharmacyclics Inc. (PCYC), Infinity Pharmaceuticals (INFI), Roche (RHHBY) and others will be a focus.
•Analysts forecast that the drugs will collectively generate up to $9B a year in annual revenue by 2020.
Sentiment: Strong Buy
Will a PR in the AM of the presentation be released, or just as it starts, or immediately after?
This old information. GERON was very careful in selecting the cells to ensure they would not go awry.
It will be interesting to see how many strong hands will hold out. If the price drops at the open a few will decided to go to ground for a while.
each cell is a unit into itself. One cell can grow to almost infinity. So if your trial has 50,000. 100,000, or 150,000 cells that is, to me, an equal number of trials. The Geron trial have shown no side effects from their STEM CELLS. Add up all the cells and you see MAMOTH things working at their own pace. All with a great safety record.
I see no difference in ACTC's or Geron's cells. It makes no difference where the cell came from. It just makes a difference where they are pointed to.
The direction of many therapies is STEM CELLS!